Literature DB >> 16081852

Activation of thymic regeneration in mice and humans following androgen blockade.

Jayne S Sutherland1, Gabrielle L Goldberg, Maree V Hammett, Adam P Uldrich, Stuart P Berzins, Tracy S Heng, Bruce R Blazar, Jeremy L Millar, Mark A Malin, Ann P Chidgey, Richard L Boyd.   

Abstract

The thymus undergoes age-related atrophy, coincident with increased circulating sex steroids from puberty. The impact of thymic atrophy is most profound in clinical conditions that cause a severe loss in peripheral T cells with the ability to regenerate adequate numbers of naive CD4+ T cells indirectly correlating with patient age. The present study demonstrates that androgen ablation results in the complete regeneration of the aged male mouse thymus, restoration of peripheral T cell phenotype and function and enhanced thymus regeneration following bone marrow transplantation. Importantly, this technique is also applicable to humans, with analysis of elderly males undergoing sex steroid ablation therapy for prostatic carcinoma, demonstrating an increase in circulating T cell numbers, particularly naive (TREC+) T cells. Collectively these studies represent a fundamentally new approach to treating immunodeficiency states in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16081852     DOI: 10.4049/jimmunol.175.4.2741

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  171 in total

1.  The origin and implication of thymic involution.

Authors:  Danielle Aw; Donald B Palmer
Journal:  Aging Dis       Date:  2011-10-28       Impact factor: 6.745

2.  MCL1 increases primitive thymocyte viability in female mice and promotes thymic expansion into adulthood.

Authors:  Jingang Gui; Amanda J Morales; Sophie E Maxey; Katherine A Bessette; Nora R Ratcliffe; John A Kelly; Ruth W Craig
Journal:  Int Immunol       Date:  2011-09-21       Impact factor: 4.823

3.  Thymus Size and Age-related Thymic Involution: Early Programming, Sexual Dimorphism, Progenitors and Stroma.

Authors:  Jingang Gui; Lisa Maria Mustachio; Dong-Ming Su; Ruth W Craig
Journal:  Aging Dis       Date:  2012-03-14       Impact factor: 6.745

4.  Regeneration of dendritic cells in aged mice.

Authors:  Serani L H van Dommelen; Alexandra Rizzitelli; Ann Chidgey; Richard Boyd; Ken Shortman; Li Wu
Journal:  Cell Mol Immunol       Date:  2010-02-01       Impact factor: 11.530

Review 5.  Cell Therapy Strategies to Combat Immunosenescence.

Authors:  Elizabeth C Stahl; Bryan N Brown
Journal:  Organogenesis       Date:  2015-11-20       Impact factor: 2.500

Review 6.  Adoptive precursor cell therapy to enhance immune reconstitution after hematopoietic stem cell transplantation.

Authors:  J L Zakrzewski; A M Holland; M R M van den Brink
Journal:  J Mol Med (Berl)       Date:  2007-02-28       Impact factor: 4.599

Review 7.  Enhancing efficacy of therapeutic vaccinations by combination with other modalities.

Authors:  James L Gulley; Ravi A Madan; Philip M Arlen
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

8.  Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.

Authors:  Andressa Ardiani; Benedetto Farsaci; Connie J Rogers; Andy Protter; Zhimin Guo; Thomas H King; David Apelian; James W Hodge
Journal:  Clin Cancer Res       Date:  2013-09-18       Impact factor: 12.531

9.  Axin expression in thymic stromal cells contributes to an age-related increase in thymic adiposity and is associated with reduced thymopoiesis independently of ghrelin signaling.

Authors:  Hyunwon Yang; Yun-Hee Youm; Yuxiang Sun; Jong-Seop Rim; Craig J Galbán; Bolormaa Vandanmagsar; Vishwa Deep Dixit
Journal:  J Leukoc Biol       Date:  2009-06       Impact factor: 4.962

10.  Androgen ablation augments prostate cancer vaccine immunogenicity only when applied after immunization.

Authors:  Yi T Koh; Andrew Gray; Sean A Higgins; Bolyn Hubby; W Martin Kast
Journal:  Prostate       Date:  2009-05-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.